Experts From Amazon Web Services and IDC Join Pyramid Executives on the Main Stage at SAPinsider 2022
14.7.2022 15:00:00 EEST | Business Wire | Press release
The Chief Technology Officer and Senior Vice President of Strategic Alliances from Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, will deliver main stage presentations with Chandana Gopal, Research Director, Future of Intelligence, IDC and Cristina Martin Greysman, WW Head of SAP on AWS Partner & Alliance Strategy at Amazon Web Services, at SAPinsider 2022, July 19 – 21 in Las Vegas.
Key Points:
- Avi Perez, Chief Technology Officer, Pyramid Analytics and Chandana Gopal, Research Director, Future of Intelligence, IDC will discuss what’s possible in their session, “Decision Intelligence: What’s Next in Data and Analytics for SAP BW and HANA.”
- Dave Henry, Senior Vice President of Strategic Alliances, Pyramid and Cristina Martin Greysman, WW Head of SAP on AWS Partner & Alliance Strategy at Amazon Web Services, will present “The ‘Beyond ERP’ Challenge: Maximizing the Use of SAP with Your Company’s Data Lake.”
- Join us at Booth 1245 on the SAPinsider 2022 exhibition floor for demos and presentations about creating additional value in SAP environments with decision intelligence.
- Come to SAPinsider 2022 in Las Vegas. Register with our discount code: PYRAMIDVIP.
The Pyramid Decision Intelligence Platform is the strongest analytics solution to run on SAP. The Pyramid Platform provides direct access. This eliminates the need to extract data out of SAP, protecting deep investment in SAP-driven business logic and security infrastructure. SAP data can also be blended with different data sources no matter where they reside to create a single view of a business and deliver reliable, consistent analytics.
Learn to Extract Maximum Value from SAP BW and HANA with Decision Intelligence
- Day 1: Tuesday, July 19. 11:30 a.m. – 12:20 p.m.
Decision Intelligence: What’s Next in Data and Analytics for SAP BW and HANA
Presenters: Avi Perez, Chief Technology Officer, Pyramid Analytics and Chandana Gopal, Research Director, Future of Intelligence, IDC.
Abstract: Many organizations that have invested in SAP BW and HANA are struggling to get insights from their data quickly without having to move it out of SAP. A key technology trend for 2022, Decision Intelligence, is what's next in analytics for SAP BW and HANA. It enables organizations to more quickly gain insights needed to make decisions, act faster, capitalize on opportunities and drive innovation. Imagine having the ability to scale for any data, any person, and any analytics need from the simple to the sophisticated. In this session, we'll talk about the barriers to getting insights from SAP, new technology developments in data and analytics, and share examples of companies who have elevated their analytics game on SAP.
- Day 2: Wednesday, July 20. 11 a.m. – 11:50 a.m.
The “Beyond ERP” Challenge:
Maximizing the Use of SAP with Your Company’s Data Lake
Presenters:
Cristina Martin Greysman, WW Head of SAP on AWS Partner & Alliance Strategy and Dave Henry, Senior Vice President of Strategic Alliances, Pyramid
Abstract: The adoption of data lakes is well underway. This includes how customers get more from their SAP investments using data lakes. However, deploying data lakes while integrating SAP systems can be daunting as customers get used to how it all comes together. Yet the use cases which combine data from SAP and data lakes are compelling. Through the lens of a customer case study, this session examines the business drivers for using data lakes with SAP. We introduce an agile approach to accessing, analyzing, and blending diverse data sets that insulates end-users from the underlying data architecture while ensuring security and strengthening IT governance.
There’s More! Attend Two Pyramid Impact20 Sessions
- Take Your SAP Investment to the Next Level with Pyramid Analytics with Kevin Kratzer, Solutions Engineer, Pyramid Analytics. Tuesday, July 19. 3:30 p.m. – 3:50 p.m.
- I Have Data Outside SAP—How Can I Get a Complete View of My Business Without Moving All My Data Around? with Matt Chapin, Solutions Engineer, Pyramid Analytics. Tuesday, July 19. 4:00 p.m. – 4:20 p.m.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for anyone to make faster, more intelligent decisions. The Pyramid Decision Intelligence Platform provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005012/en/
Contact information
UK
Susie Evershed
Resonance
+44 7966 145092
pyramidanalytics@resonancecrowd.com
US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com
Chas Kielt
Vice President of Global Corporate Communications, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 20266.7.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress 2026 on July 2 in Munich, Germany. BOT+BAL demonstrated clinically meaningful long-term survival in a heavily pretreated patient population with historically limited benefit from conventional immune checkpoint inhibitors and few durable treatment options after progression on standard therapies. With extended follow-up, median overall survival was 21.2 months and the three-year overall survival rate was 33%, with the Kaplan-Meier curve showing a plateau beyond two years
LTM Launches BlueVerse™ RightLogic to Address Cyber Risk in AI Era6.7.2026 12:12:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has launched BlueVerse™ RightLogic, a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. AI is now capable of autonomously identifying and exploiting vulnerabilities, while exposure across infrastructure, applications and supply chains continue to expand. This has elevated cyber risk from a technology concern to a board-level priority, with enterprises struggling to maintain visibility and respond at the speed of emerging threats. BlueVerse RightLogic addresses this gap by providing a unified, business-aligned view of enterprise exposure and enabling a shift from fragmented, point-in-time assessments to continuous, evidence-led risk management. The framework combines an end-to-end AI and cyber exposure assessment engine with a structured execution model that spans from assessment to remediation. At the cor
Media Release: Financial Worries Rise and Match Health Concerns as Cost-of-Living Pressures Mount in 20266.7.2026 11:00:00 EEST | Press release
Households around the world are feeling the strain of the rising cost of living, with financial pressure increasingly shaping everyday choices and long-term confidence. Finances and health are now tied as the top global worries, at 48% each, followed by concerns about the future at 35%, according to consumer surveys in 10 countries published in “The Allianz 3am Report 2026.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260703907741/en/ Allianz / IPSOS “What Worries the World” Study, April – June 2026. Financial worries, which include concerns about “rising cost of living” (71%) and “insufficient income” (51%), increased in seven out of eight countries surveyed year over year, moving up in the ranking of top three worries in Brazil, France, Germany, and the U.K., while remaining stable in Italy. The strongest increases are observed in Australia and Indonesia, where financial concerns have remained the leading worry, as well
HAZAMA ANDO Becomes an Official Partner in Helical Fusion’s Commercial Fusion Initiative and Signs MoU Toward Construction of the Fusion Pilot Plant6.7.2026 09:40:00 EEST | Press release
Helical Fusion Co., Ltd. (“Helical Fusion”), a Japan-based fusion energy startup developing fusion power plants, and HAZAMA ANDO CORPORATION (“HAZAMA ANDO”), a long-established Japanese general contractor, today announced that HAZAMA ANDO has become an Official Partner in the Helix Program, Helical Fusion’s commercial fusion initiative. The two companies have also signed a memorandum of understanding (“MoU”) to collaborate toward the construction of Helix KANATA, Helical Fusion’s Fusion Pilot Plant targeted for the 2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706176052/en/ (L-R) Kazuhiko Kuniya (Representative Director and President, HAZAMA ANDO CORPORATION) and Takaya Taguchi (Co-Founder and CEO, Helical Fusion Co., Ltd.) at a press conference in Tokyo on July 6, 2026. Fusion energy has the potential to shift the foundation of energy from natural resources to advanced technology by reproducing, on Earth, the sam
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 08:15:00 EEST | Press release
Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discovery and development of a novel class of payloads for antibody-drug conjugates. The company's platform is built around next-generation N-myristoyltransferase inhibitor (NMTi) payloads, a differentiated mechanism of action designed to address the narrow therapeutic windows and tolerability challenges that have limited earlier generations of ADCs, such as TOPO-1 and tubulin inhibitor payload classes. Myricx Bio's two lead ADC assets, directed towards the established targets B7-H3 and HER2, are designed to bring this differentiated approach to patients across a broad ra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom